Please assess the completion status of the following clinical trial:

Trial Title: Management of Decompensated HCV Cirrhotic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic active HCV proved by the positivity of HCV RNA, elevated transaminases.~* CTP score was \>9, MELD score was \<29~* Decompensated cirrhosis with frequent hepatic encephalopathy (HE) or difficult to treat ascites~Exclusion Criteria:~* exposure to previous antiviral therapy~* hepatocellular carcinoma~* other causes of liver diseases or mixed causes (excessive alcohol consumption, autoimmune liver disease)~* previous liver transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- cases (Type: ACTIVE_COMPARATOR): patients with decompensated cirrhosis~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)
- control group (Type: PLACEBO_COMPARATOR): the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).